Sanofi/€SAN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Ticker
€SAN
Sector
Primary listing
PAR
Employees
82,878
Headquarters
Website
Sanofi Metrics
BasicAdvanced
€101B
11.24
€7.36
0.44
€3.92
4.74%
Price and volume
Market cap
€101B
Beta
0.44
52-week high
€110.88
52-week low
€76.73
Average daily volume
23K
Dividend rate
€3.92
Financial strength
Current ratio
1.274
Quick ratio
0.811
Long term debt to equity
20.951
Total debt to equity
31.709
Dividend payout ratio (TTM)
52.29%
Interest coverage (TTM)
16.91%
Profitability
EBITDA (TTM)
12,082
Gross margin (TTM)
71.32%
Net profit margin (TTM)
19.95%
Operating margin (TTM)
20.51%
Effective tax rate (TTM)
19.24%
Revenue per employee (TTM)
€550,000
Management effectiveness
Return on assets (TTM)
4.65%
Return on equity (TTM)
9.00%
Valuation
Price to earnings (TTM)
11.239
Price to revenue (TTM)
2.242
Price to book
1.45
Price to tangible book (TTM)
10.91
Price to free cash flow (TTM)
12.206
Free cash flow yield (TTM)
8.19%
Free cash flow per share (TTM)
6.78
Dividend yield (TTM)
4.74%
Forward dividend yield
4.74%
Growth
Revenue change (TTM)
15.65%
Earnings per share change (TTM)
117.96%
3-year revenue growth (CAGR)
2.85%
10-year revenue growth (CAGR)
3.35%
3-year earnings per share growth (CAGR)
11.55%
10-year earnings per share growth (CAGR)
7.23%
3-year dividend per share growth (CAGR)
5.59%
10-year dividend per share growth (CAGR)
3.24%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Bulls say / Bears say
Sanofi raised its full-year sales growth guidance to high single digits, supported by a 21.1% surge in Dupixent sales to €3.83 billion—beating analyst expectations.
In Q1, Sanofi’s business operating income grew 20.1% to €2.90 billion, outperforming estimates on strong results from Dupixent and the newborn respiratory virus treatment Beyfortus.
Acquiring Blueprint Medicines for over $9 billion adds the approved systemic mastocytosis drug Ayvakit and a late-stage immunology pipeline, strengthening Sanofi’s rare disease portfolio.
Sanofi’s new eczema candidate amlitelimab underperformed, as its efficacy in late-stage trials did not significantly exceed that of Dupixent. This led to a stock decline of over 9% and raised concerns about its potential to replace a blockbuster product.
Despite strong demand for Dupixent, Sanofi’s Q2 core business operating income—excluding one-off items—rose only 3.3% to €2.46 billion, missing analyst estimates and underscoring margin pressure.
The €9.5 billion acquisition of Blueprint Medicines, while expanding Sanofi’s immunology pipeline, also increases debt and brings integration and milestone execution risks that could impact returns.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SAN) has a market cap of €101B as of October 14, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SAN) stock is 11.24 as of October 14, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SAN) stock pays dividends to shareholders. As of October 14, 2025, the dividend rate is €3.92 and the yield is 4.74%. Sanofi has a payout ratio of 52.29% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SAN) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SAN) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.